Introduction {#section1-1479972318809476}
============

Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) is a devastating condition that occurs in the clinical course of IPF.^[@bibr1-1479972318809476][@bibr2-1479972318809476][@bibr3-1479972318809476]--[@bibr4-1479972318809476]^ During the heterogeneous clinical course of IPF, patients with more severe disease seem to more frequently progress to AE-IPF.^[@bibr5-1479972318809476]^ In addition, one of the most important causes of disease progression and death is AE-IPF,^[@bibr6-1479972318809476],[@bibr7-1479972318809476]^ and AE-IPF accounts for 30--40% of the deaths in patients with IPF.^[@bibr8-1479972318809476],[@bibr9-1479972318809476]^ The 2007 criteria for diagnosis of AE-IPF were extremely strict, requiring careful exclusion of pulmonary infection, left heart failure, pulmonary embolism, and identifiable causes of acute lung injury.^[@bibr3-1479972318809476]^ However, some of these causes, including infection and drug toxicity, are allowed as triggers of AE in the 2016 updated criteria for AE-IPF.^[@bibr10-1479972318809476]^ Because these triggers sometimes coexist with AE-IPF in clinical practice, these amendments to the criteria are now easier to apply.

AE occurs not only in IPF but also in other idiopathic interstitial pneumonia (IIP) or connective tissue disease-associated interstitial pneumonia (CTD-IP).^[@bibr11-1479972318809476][@bibr12-1479972318809476][@bibr13-1479972318809476]--[@bibr14-1479972318809476]^ Although AE of CTD-IP (AE-CTD-IP) occurs less frequently than AE-IPF, this condition also has a great impact on patient prognosis.^[@bibr12-1479972318809476]^ Therefore, AE-CTD-IP is also the most important event in the clinical course of CTD. In patients with CTD, especially those with rheumatoid arthritis (RA), immunosuppressive agents such as steroids, immunosuppressants, and novel biological products are frequently administered to treat CTD. Thus, infectious pneumonia and drug-induced pneumonitis are important differential diagnoses, especially in this setting. However, the specific features of AE-CTD-IP in clinical practice, such as pulmonary function tests before AE and inflammatory findings or high-resolution computed tomography (HRCT) findings at AE, have not been well-established compared with those of AE-IPF.

In this study, we evaluated important clinical factors for differential diagnosis and prognosis of AE-CTD-IP. Furthermore, these factors were compared with those of AE-IPF. To the best of our knowledge, this is the first study to show detailed clinical differences between AE-CTD-IP and AE-IPF.

Patients and methods {#section2-1479972318809476}
====================

Study design and subjects {#section3-1479972318809476}
-------------------------

Fifteen patients who were diagnosed and treated for AE-CTD-IP at our hospital between 1997 and 2015 were retrospectively reviewed. Thirty-seven patients (48 episodes in total) with AE-IPF, who were treated at our hospital in the same period, were also recorded and data were compared with those of AE-CTD-IP. All patients with IPF met the 2011 international consensus criteria for IPF.^[@bibr4-1479972318809476]^

AE of IP was diagnosed according to the modified diagnostic criteria described by Collard et al.^[@bibr3-1479972318809476]^ Briefly, the diagnostic criteria for diagnosis of AE-IP were as follows: (1) previous or concurrent diagnosis of IP; (2) unexplained worsening or development of dyspnea within 30 days; (3) HRCT with new bilateral ground-glass abnormality and/or consolidation superimposed on a background reticular or honeycomb pattern; (4) no evidence of pulmonary infection; and (5) exclusion of alternative causes including left heart failure, pulmonary embolism, or an identifiable cause of acute lung injury. Patients enrolled in this study also met the newly proposed criteria in 2016.^[@bibr10-1479972318809476]^ The study protocol was approved by the Ethics Committee of Hamamatsu University School of Medicine (approval number E16-065). All procedures in this study were performed in accordance with the 1964 Helsinki declaration and its later amendments.

Data collection {#section4-1479972318809476}
---------------

Clinical data were obtained from medical records. Disease severity of IPF within 12 months before the AE event was assessed using pulmonary function tests and findings on HRCT. Blood samples were collected at AE-IP.

Evaluation of HRCT findings {#section5-1479972318809476}
---------------------------

The extent of lung opacities was measured on three HRCT slices: at the bifurcation of the trachea, at the bases of the lower lobes, and at the midpoint between the other two slices. The extent of fibrosis in each lobe was scored using the following system: 0, none; 1, 1--10%; 2, 11--25%; 3, 26--50%; 4, 51--75%; and 5, 76--100%. The sum of the scores from five lobes (0--25) was used to express the extent of reticular opacity, honeycombing, consolidation, and ground-glass opacity in each patient. The pattern of acute exacerbation of IP on HRCT was classified as (1) peripheral, (2) multifocal, or (3) diffuse as reported by Akira.^[@bibr15-1479972318809476]^ The HRCT findings were reviewed by two observers.

Statistical analysis {#section6-1479972318809476}
--------------------

Statistical analyses were performed using StatView J-4.5 (SAS Institute Inc., Cary, North Carolina, USA). Categorical data were compared using the *χ* ^2^ test or Fisher's exact probability test for independence, and continuous data were compared using the unpaired *t*-test. Continuous data at different time points in the same patient were compared using the paired *t*-test. Overall survival of patient groups was estimated using Kaplan--Meier curves and was compared between groups using the log-rank test. The relationships between variables and mortality were evaluated using the Cox proportional hazards regression analysis. All tests were two-sided and statistical significance was set at *p* \< 0.05.

Results {#section7-1479972318809476}
=======

Clinical characteristics, physical examination findings, and treatments in all patients with AE-CTD-IP {#section8-1479972318809476}
------------------------------------------------------------------------------------------------------

Clinical characteristics of all patients with AE-CTD-IP, including physical examination findings and preceding treatments, are shown in [Table 1](#table1-1479972318809476){ref-type="table"}. Patients had a median age of 71 years at AE-CTD-IP and 11 patients were male. The median observation period was 56 months. A breakdown of CTD-diagnosis is shown in [Figure 1](#fig1-1479972318809476){ref-type="fig"}. Patients with AE-CTD-IP comprised nine with rheumatoid arthritis, three with microscopic polyarthritis, two with systemic sclerosis, and one with microscopic polyarteritis and Sjogren syndrome. CTD activity before AE was not high in all patients. IP preceding CTD diagnosis was found in 6 of 15 patients ([Table 1](#table1-1479972318809476){ref-type="table"}). Surgical lung biopsy was performed in four patients. Two showed a usual interstitial pneumonia pattern and the other two showed a nonspecific interstitial pneumonia pattern.

###### 

Clinical characteristics, physiological data, and treatments in patients with AE-CTD-IP.

![](10.1177_1479972318809476-table1)

                                                  *n* = 15, median (range)
  ----------------------------------------------- --------------------------
  Age, year                                       71 (57, 85)
  Sex, male/female                                11/4
  Smoking, never/ex/current                       2/13/0
  Pack-year of smoking                            27.5 (0, 90)
  Surgical lung biopsy, ±                         4/11
  Period from CTD-diagnosis to AE, months         64 (0, 365)
  IP preceding CTD-diagnosis, ±                   6/9
  Dyspnea on effort, mMRC 0/1/2/3/4/unknown       1/1/3/2/6/2
  Clubbed finger, ±                               3/12
  Preceding treatments with steroids, ±           9/6
  Administration dose of steroids, mg/day         5 (0, 30)
  Preceding treatments with immunosuppresant, ±   8/7
  Preceding treatments with methotrexate, ±       5/10
  Preceding oxygen therapy, ±                     4/11
  Observation period, months                      56 (0, 228)

AE: acute exacerbation, CTD: connective tissue disease, IP: interstitial pneumonia, mMRC: modified Medical Research Council.

![A breakdown of connective tissue disease (CTD)-diagnosis in 15 patients with acute exacerbation of CTD-associated interstitial pneumonia (AE-CTD-IP). Patients with AE-CTD-IP comprised nine with rheumatoid arthritis, three with microscopic polyarthritis, two with systemic sclerosis, and one with microscopic polyarteritis and Sjogren syndrome. RA: rheumatoid arthritis, mPA: microscopic polyarthritis, SSc: systemic sclerosis.](10.1177_1479972318809476-fig1){#fig1-1479972318809476}

Treatment with steroids was preceded in nine patients. Treatment with immunosuppressants was preceded in eight, five of whom with methotrexate. In total, 11 patients with CTD-IP were treated with steroids and/or immunosuppressants. Regarding anti-fibrotic medicine, pirfenidone was administered in one patient. Four patients received long-term oxygen therapy before AE-CTD-IP. During the observation period, all patients presented with their first AE episode and no patient repeated AE-CTD-IP.

Comparison of data between patients with AE-CTD-IP and those with AE-IPF {#section9-1479972318809476}
------------------------------------------------------------------------

Clinical data, including physiological data, laboratory findings, HRCT findings, and treatments of patients with AE-CTD-IP (shown in [Table 2](#table2-1479972318809476){ref-type="table"}) were compared with clinical data from AE-IPF patients. While all patients with AE-CTD-IP presented with their first AE episode, several patients with AE-IPF repeated AE (*p* = 0.098). Percent-predicted forced vital capacity (%FVC) within 1 year before AE in patients with AE-CTD-IP was significantly higher than in those with AE-IPF (median 94.8 and 56.3%, respectively, *p* \< 0.001, [Figure 2(a)](#fig2-1479972318809476){ref-type="fig"}). Furthermore, the extent of honeycombing on HRCT within 1 year before AE in patients with AE-CTD-IP was significantly less severe than in those with AE-IPF (*p* = 0.020, [Figure 2(b)](#fig2-1479972318809476){ref-type="fig"}). The extent of honeycombing at AE was also less severe (*p* = 0.007; Online Supplemental Table S1). Frequency of preceding treatments, including long-term oxygen therapy, was not different between groups. Administration of methotrexate was discontinued in all cases. At AE, the PaO~2~/FiO~2~ (P/F) ratio, extent score of all findings on HRCT, and HRCT pattern were not different between groups. However, the white blood cell count (12.0 vs. 9.9 × 10^3^/μL; *p* = 0.023) and neutrophils (11.3 vs. 7.4 × 10^3^/μL; *p* = 0.010) in peripheral blood and serum C-reactive protein (CRP, 10.2 vs. 6.7; *p* = 0.027) were significantly higher in patients with AE-CTD-IP than in those with AE-IPF ([Table 2](#table2-1479972318809476){ref-type="table"}). In addition, the incidence of fever tended to be higher in patients with AE-CTD-IP than in those with AE-IPF (53.3 vs. 29.1%, *p* = 0.086). All patients with AE-CTD-IP or AE-IPF were treated with steroid pulse therapy after hospital admission (methylprednisolone 1000 mg/day for 3 days) followed by a tapering dose of prednisolone. Treatments with an immunosuppressant (cyclophosphamide or cyclosporine) and/or direct hemoperfusion with a polymyxin B-immobilized fiber column (PMX-DHP) (PMX; Toray Medical Co., Ltd, Tokyo, Japan)^[@bibr16-1479972318809476],[@bibr17-1479972318809476]^ were added to steroid therapy in a large proportion of patients. These treatments were commenced as soon as possible after admission concomitantly with the administration of antibiotics. These AE treatments were not different between groups. However, the period from admission to the beginning of AE treatments (median, 4 vs. 1 day; *p* = 0.003) and that to the beginning of PMX-DHP (median, 10 vs. 1 day; *p* \< 0.001) were significantly longer in patients with AE-CTD-IP than in those with AE-IPF ([Table 2](#table2-1479972318809476){ref-type="table"}).

###### 

Comparison of data between patients with AE-CTD-IP and those with AE-IPF.

![](10.1177_1479972318809476-table2)

  ----------------------------------------------------------------------------------------------------------------------------------------------------
                                                                AE-CTD-IP (*n* = 15, median (range))   AE-IPF (*n* = 48, median (range))   *p* Value
  ------------------------------------------------------------- -------------------------------------- ----------------------------------- -----------
  Age, year                                                     71 (57, 85)                            69 (50, 84)                         0.273

  Sex, male/female                                              11/4                                   45/3                                0.049^a^

  Smoking, never/ex/current                                     2/13/0                                 4/39/5                              0.386

  Pack-year of smoking                                          28 (0, 90)                             37 (0, 81)                          0.574

  Observation period, months                                    56 (0, 228)                            53 (2, 205)                         0.829

  The number of AE, 1/2/3                                       15/0/0                                 36/11/1                             0.098

  Preceding treatments, ±                                       11 / 4                                 31/17                               0.755^a^

  Preceding treatment with steroids, ±                          9 / 6                                  23 / 25                             0.414

  Preceding oxygen therapy, ±                                   4 / 11                                 16 / 32                             0.756^a^

  Fever at AE, ±                                                8 / 7                                  14 / 34                             0.086

  Peripheral blood WBC at AE, ×103/μL                           12.0 (7.4, 22.8)                       9.9 (1.9, 20.0)                     0.023

  Peripheral blood neutrophils at AE, ×103/μL                   11.3 (6.3, 19.4)                       7.4 (1.5, 18.2)                     0.010

  Peripheral blood platelets at AE, ×103/μL                     25.7 (8.1, 84.0)                       21.0 (11.3, 46.2)                   0.001

  Serum CRP at AE, mg/dL                                        10.2 (1.5, 31.8)                       6.7 (0.9, 23.7)                     0.027

  Serum LDH at AE, IU/L                                         405 (202, 815)                         347 (183, 693)                      0.089

  Serum KL-6 at AE, U/mL                                        1483 (445, 2779)                       1550 (481, 6404)                    0.243

  Serum SP-D at AE, ng/mL                                       285 (74, 2950)                         366 (23, 1330)                      0.284

  P/F ratio at AE                                               181 (57, 290)                          168.5 (38, 386)                     0.814

  Extent scores on HRCT at AE (full score: 25)                  19 (10, 25)                            21 (13, 25)                         0.314

  HRCT pattern at AE,\                                          \                                      \                                   \
  peripheral/multifocal/diffuse/unknown                         1/3/10/1                               3/5/37/3                            0.998

  Period from admission to the beginning of AE-treatment, day   4 (0, 13)                              1 (0, 17)                           0.003

  Period from admission to the beginning of PMX-DHP, day        10 (7, 13)                             1 (0, 17)                           \<0.001

  Administration of steroid pulse therapy at AE, ±              15/0                                   48/0                                NS

  Administration of immunosuppressant at AE, ±                  9/6                                    36/12                               0.272^a^

  Treatment with PMX-DHP, ±                                     5/10                                   26/22                               0.237^a^

  Intubation at AE, ±                                           5/10                                   12/36                               0.523^a^
  ----------------------------------------------------------------------------------------------------------------------------------------------------

AE: acute exacerbation, CTD: connective tissue disease, IP: interstitial pneumonia, HRCT: high-resolution computed tomography, CRP: C-reactive protein, LDH: lactate dehydrogenase, KL-6: Krebs von den Lungen-6, SP-D: surfactant protein D, P/F: PaO~2~/FiO~2~, PMX-DHP: direct hemoperfusion with a polymyxin B-immobilized fiber column. NS: not significant.

^a^ Fisher's exact probability test.

![Comparison of pulmonary function test or HRCT findings between AE-CTD-IP and AE-IPF. (a) %FVC within one year before AE was evaluated. %FVC of patients with AE-CTD-IP was significantly higher than in those with AE-IPF (median 94.8 and 56.3%, respectively, *p* \< 0.001). (b) The extent of honeycombing on HRCT within 1 year before AE was graded. Honeycombing was significantly less severe in patients with AE-CTD-IP than in those with AE-IPF (*p* = 0.020). HRCT: high-resolution computed tomography; AE-CTD-IP: acute exacerbation of connective tissue disease-associated interstitial pneumonia; IPF: idiopathic pulmonary fibrosis; %FVC: percent-predicted forced vital capacity.](10.1177_1479972318809476-fig2){#fig2-1479972318809476}

Mortality rate and prognostic factors {#section10-1479972318809476}
-------------------------------------

Of 15 patients with AE-CTD-IP, 5 died within 1 month of onset (mortality rate, 33.3%), seven died within 3 months (mortality rate, 46.7%) and 11 died during the study period (mortality rate, 73.3%). Within 3 months of AE-IPF onset, six patients died of respiratory failure caused by AE-CTD-IP and one died of gastrointestinal bleeding after beginning of steroid treatment. Kaplan--Meier survival curves from the first AE onset are shown in [Figure 3](#fig3-1479972318809476){ref-type="fig"}. The 3-month survival rate was not significantly different between the two groups (log-rank test, *p* = 0.171). However, the survival rate of AE-CTD-IP tended to be worse than that of AE-IPF. The results of univariate Cox proportional hazards models of survival in both groups to identify prognostic factors within 3 months of AE onset are shown in [Table 3](#table3-1479972318809476){ref-type="table"}. The period from IP diagnosis to AE was a significant prognostic factor in patients with AE-CTD-IP, while it was not in those with AE-IPF (hazard ratio (HR): 1.011, *p* = 0.023 and HR 0.999, *p* = 0.820, respectively). Intubation at AE was also a worse prognostic factor in patients with AE-CTD-IP (HR 8.080, p = 0.015). Higher neutrophils in peripheral blood at AE tended to be a worse prognostic factor in patients with AE-CTD-IP (HR: 1.000, *p* = 0.076), while it was a significant factor in those with AE-IPF (HR: 1.000, *p* = 0.002). The extent score on HRCT at AE tended to be a significant factor in both groups (HR: 1.211, *p* = 0.097 and HR: 1.210, *p* = 0.055, respectively). Neither treatment with immunosuppressant nor PMX-DHP was a prognostic factor in patients with AE-CTD-IP (HR: 1.999, *p* = 0.409 and HR 0.851, *p* = 0.815, respectively). Multivariate Cox proportional hazards analyses for prognostic factors could not be conducted because of low statistical power.

![Kaplan--Meier survival curves from the first AE onset. Of 15 patients with AE-CTD-IP, 5 died within 1 month of onset (mortality rate, 33.3%), seven died within 3 months (mortality rate, 46.7%) and 11 died during the study period (mortality rate, 73.3%). The 3-month survival rate was not significantly different between patients with AE-CTD-IP and those with AE of IPF (log-rank test, *p* = 0.171). The survival rate of AE-CTD-IP tended to be worse than that of AE-IPF. AE: acute exacerbation; AE-CTD-IP: acute exacerbation of connective tissue disease-associated interstitial pneumonia; IPF: idiopathic pulmonary fibrosis.](10.1177_1479972318809476-fig3){#fig3-1479972318809476}

###### 

Univariate cox proportional hazards models of survival.

![](10.1177_1479972318809476-table3)

  Variables                                                     AE-CTD-IP   AE-IPF           
  ------------------------------------------------------------- ----------- -------- ------- -------
  Age, year                                                     1.030       0.497    1.023   0.616
  Sex, male                                                     3.178       0.286    0.811   0.843
  Period from IP-diagnosis to AE, months                        1.011       0.023    0.999   0.820
  Extent score on HRCT before AE^a^                             0.997       0.980    1.181   0.107
  FVC before AE^a^, % pred                                      1.066       0.354    0.974   0.307
  Preceding oxygen therapy, +                                   3.382       0.114    3.416   0.053
  Fever at AE, +                                                1.263       0.760    0.505   0.388
  Peripheral blood WBC at AE, /μL                               1.000       0.208    1.000   0.025
  Peripheral blood neutrophils at AE, /μL                       1.000       0.076    1.000   0.002
  Serum CRP at AE, mg/dL                                        1.035       0.354    0.999   0.961
  Serum LDH at AE, IU/L                                         1.001       0.631    1.005   0.071
  Serum KL-6 at AE, U/mL                                        1.000       0.579    1.000   0.970
  Serum SP-D at AE, ng/mL                                       1.001       0.163    0.999   0.673
  P/F ratio at AE                                               0.993       0.179    0.995   0.215
  Extent score on HRCT at AE                                    1.211       0.097    1.210   0.055
  Period from admission to the beginning of AE-treatment, day   1.020       0.821    1.072   0.369
  Intubation at AE, +                                           8.080       0.015    3.045   0.079

AE: acute exacerbation, CTD: connective tissue disease, IP: interstitial pneumonia, HRCT: high-resolution computed tomography, FVC: forced vital capacity, CRP: C-reactive protein, LDH: lactate dehydrogenase, KL-6: Krebs von den Lungen-6, SP-D: surfactant protein D, P/F: PaO~2~/FiO~2~.

^a^ Pulmonary function tests, severity scores, HRCT, and serum markers were evaluated within 12 months before AE-IPF.

Discussion {#section11-1479972318809476}
==========

In this study, we retrospectively reviewed 15 patients with AE-CTD-IP and compared their clinical features with those of AE-IPF. Patients with AE-CTD-IP had significantly higher %FVC and lower extent of honeycombing on HRCT within 1 year before AE. At AE, patients with AE-CTD-IP showed a higher white blood cell count and CRP level, and the period from admission to the beginning of AE treatment, including PMX-DHP, was significantly longer than those of AE-IPF. Finally, patients with AE-CTD-IP had a poor prognosis as that of AE-IPF. To the best of our knowledge, this is the first report to show the detailed clinical features of AE-CTD-IP compared with those of AE-IPF.

AE-CTD-IP less frequently occurs than AE-IPF. The 1-year incidence of AE-CTD-IP was 1.25--3.3%,^[@bibr11-1479972318809476],[@bibr12-1479972318809476]^ while that of AE-IPF was 4.8--14.2%,^[@bibr2-1479972318809476],[@bibr18-1479972318809476]^ Along with AE-IPF, early diagnosis of AE is quite important to save patients with AE-CTD-IP. However, early diagnosis of AE-CTD-IP is sometimes difficult for an attending doctor in clinical practice because many patients with CTD-IP are receiving steroids, immunosuppressants, and biological products before AE. This is the contrasting treatment of IPF, in which immunosuppressive medication is ineffective or sometimes harmful in their clinical course.^[@bibr4-1479972318809476],[@bibr19-1479972318809476]^ Under these treatments, the most important differential diagnosis is pulmonary infection, such as pneumocystis pneumonia and cytomegalovirus infection. In this study, patients with AE-CTD-IP showed more inflammatory findings and increased levels of white blood cells and CRP compared with patients with AE-IPF, and clinicians were reluctant to start treatments for AE. Although these infections were thoroughly excluded before the treatments for AE-CTD-IP at our hospital, this process took time and was related to the delay in commencing of treatments for AE. Furthermore, administration of methotrexate for many patients with RA (five of nine patients) increased the possibility of drug-induced pneumonitis in clinical practice. As just described, these two differential diagnoses were related to the treatment delay in patients with AE-CTD-IP.

AE-IPF occurs more often in a patient's advanced stage than in early stage.^[@bibr5-1479972318809476]^ Surprisingly, in AE-CTD-IP, %FVC was far higher and the extent of honeycombing was lower before AE than those of AE-IPF. These data indicate that AE suddenly occurs, even in the early stage of IP in patients with CTD-IP, which is not true for patients with IPF. Whereas the exact mechanism of this frequent incidence in the early stage has been unclear, many patients (11 of 15) with CTD-IP were treated with steroids and/or immunosuppressants before AE. In these settings, some viral infection or some drug toxicity may have been triggers for AE-CTD-IP. Therefore, clinicians should pay more attention to the appearance of AE under immunosuppressive therapies in patients with CTD-IP.

Regarding the prognosis of AE-CTD-IP, our previous study^[@bibr12-1479972318809476]^ and Park et al.^[@bibr11-1479972318809476]^ reported poor survival in patients with AE-CTD-IP. The mortality rates in these small studies were 83.3%^[@bibr12-1479972318809476]^ and 100%,^[@bibr11-1479972318809476]^ respectively. However, two other studies showed better survival and the mortality rates were 33% (90 days)^[@bibr13-1479972318809476]^ and 30%,^[@bibr14-1479972318809476]^ respectively. Thus, the prognosis of AE-CTD-IP remains controversial. In the present study, patients with AE-CTD-IP tended to have relatively worse prognosis than those with AE-IPF. This may result from the delay in commencing AE-treatment, including PMX-DHP, because of taking time to exclude infection and drug-induced pneumonitis. Although the period from admission to the onset of AE-treatments was not a prognostic factor, this may be because of the small number of patients in this study and delayed commencement of AE treatment in many of these patients. In these two decades, treatments for AE-IP have significantly evolved and novel treatments have emerged.^[@bibr10-1479972318809476]^ Prompt diagnosis of AE-CTD-IP and early initiation of immunosuppressive therapies in combination with recombinant thrombomodulin^[@bibr20-1479972318809476]^ or PMX-DHP,^[@bibr16-1479972318809476],[@bibr17-1479972318809476]^ which showed promising treatment effects on AE-IPF, may improve this poor survival in the near future.

This study has a number of limitations. First, only a small number of patients with AE-CTD-IP were included. This matter limited the statistical power to find differences between patients with AE-CTD-IP and those with AE-IPF. Furthermore, these patients had several different CTDs; therefore, the patient cohorts were quite heterogenous. Second, the data were retrospectively collected. Finally, the treatment for AE-CTD-IP was not uniform. A larger and prospective study is needed to further evaluate the clinical features and treatments for AE-CTD-IP.

In conclusion, we evaluated 15 patients with AE-CTD-IP and compared their clinical features with those of AE-IPF. AE-CTD-IP suddenly occurred, even in the early stage of CTD-IP, and showed higher inflammatory status at AE compared with AE-IPF. The period from admission to the beginning of AE treatment, including PMX-DHP, was significantly longer than that of AE-IPF, and patients with AE-CTD-IP showed poor prognosis, similar to AE-IPF patients. These findings should encourage doctors in clinical settings to promptly diagnose and treat patients with AE-CTD-IP. Further validation is needed to improve the poor survival in patients with AE-CTD-IP.
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